These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8714617)

  • 81. Report on immunosuppressive therapy.
    Arch Immunol Ther Exp (Warsz); 1975; 23(2):161-76. PubMed ID: 1147741
    [No Abstract]   [Full Text] [Related]  

  • 82. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis.
    Goodin DS
    Neuroepidemiology; 1999; 18(2):53-63. PubMed ID: 10023128
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Eyebrow alopecia associated with cladribine treatment for multiple sclerosis.
    Budimkic MS; Ivanovic J; Momcilovic N; Mesaros S; Drulovic J
    Neurol Sci; 2023 Oct; 44(10):3735-3736. PubMed ID: 37249666
    [No Abstract]   [Full Text] [Related]  

  • 84. [Immunosuppressive agents in the treatment of autoimmune diseases. Present status in the world and domestic literature].
    Nouza K
    Cas Lek Cesk; 1969 Oct; 108(46):1365-74. PubMed ID: 4901241
    [No Abstract]   [Full Text] [Related]  

  • 85. Breast carcinoma presenting as immune thrombocytopenic purpura.
    Wahid FS; Fun LC; Keng CS; Ismail F
    Int J Hematol; 2001 Apr; 73(3):399-400. PubMed ID: 11345211
    [No Abstract]   [Full Text] [Related]  

  • 86. Severe skin reactions associated with cladribine in people with multiple sclerosis.
    Mateo-Casas M; Reyes S; O'Toole EA; De Trane S; Yildiz O; Allen-Philbey K; Mathews J; Baker D; Giovannoni G; Schmierer K
    Mult Scler Relat Disord; 2020 Aug; 43():102140. PubMed ID: 32454296
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
    Ceronie B; Jacobs BM; Baker D; Dubuisson N; Mao Z; Ammoscato F; Lock H; Longhurst HJ; Giovannoni G; Schmierer K
    J Neurol; 2018 May; 265(5):1199-1209. PubMed ID: 29550884
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Methodologic and ethical implications of immunosuppressive therapy in multiple sclerosis].
    Szobor A
    Orv Hetil; 1984 Mar; 125(11):673. PubMed ID: 6700975
    [No Abstract]   [Full Text] [Related]  

  • 89. The effect of cladribine on T(1) 'black hole' changes in progressive MS.
    Filippi M; Rovaris M; Rice GP; Sormani MP; Iannucci G; Giacomotti L; Comi G
    J Neurol Sci; 2000 May; 176(1):42-4. PubMed ID: 10865091
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The cladribine trial in secondary progressive multiple sclerosis: A reanalysis.
    Beutler E; Koziol JA
    Neuroepidemiology; 2000; 19(2):109-12. PubMed ID: 10686535
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The new era of immunosuppressive therapy in autoimmune diseases.
    Bach JF
    Transplant Proc; 1991 Dec; 23(6):3319-21. PubMed ID: 1750093
    [No Abstract]   [Full Text] [Related]  

  • 92. Cladribine treatment of multiple sclerosis.
    Grieb P; Ryba M; Stelmasiak Z; Nowicki J; Solski J; Jakubowska B
    Lancet; 1994 Aug; 344(8921):538. PubMed ID: 7980785
    [No Abstract]   [Full Text] [Related]  

  • 93. Cladribine treatment of multiple sclerosis.
    Polman CH; Koetsier JC
    Lancet; 1994 Aug; 344(8921):537; author reply 537-8. PubMed ID: 7980784
    [No Abstract]   [Full Text] [Related]  

  • 94. Cladribine treatment of multiple sclerosis.
    Reilly D
    Lancet; 1994 Aug; 344(8921):537; author reply 537-8. PubMed ID: 7914625
    [No Abstract]   [Full Text] [Related]  

  • 95. [Immunosuppressive agents in the treatment of glomerular nephropathies].
    Aparicio M; Cledes J
    Cah Med; 1970 Nov; 11(13):1137-41. PubMed ID: 5502824
    [No Abstract]   [Full Text] [Related]  

  • 96. Autoimmune-induced focal meningoencephalitis.
    Rodríguez Sanz A; Tallón Barranco A; Díez-Tejedor E
    Neurologia; 2013; 28(1):63-4. PubMed ID: 21907463
    [No Abstract]   [Full Text] [Related]  

  • 97. [Conference reports].
    Pelletier J
    Rev Neurol (Paris); 2000 Jul; 156(6-7):684-5. PubMed ID: 10891809
    [No Abstract]   [Full Text] [Related]  

  • 98. Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial.
    Koziol JA; Lucero A; Sipe JC; Romine JS; Beutler E
    Can J Neurol Sci; 1999 Nov; 26(4):283-9. PubMed ID: 10563213
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Multiple sclerosis and the autoimmunization process. Treatment by antimitotics].
    Aimard G; Girard PF; Raveau J
    Lyon Med; 1966 Feb; 215(6):345-52. PubMed ID: 5906182
    [No Abstract]   [Full Text] [Related]  

  • 100. [Immunosuppressive agents].
    Mertens HG
    Med Welt; 1980 Oct; 31(40):1440-3. PubMed ID: 7464499
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.